Ackman defends Valeant, hints at more changes

BOSTON/NEW YORK (Reuters) - Billionaire investor William Ackman on Monday mounted a vigorous defense of Valeant Pharmaceuticals , ruling out any sale of the drug company's "crown jewel" assets but saying price cuts and even a new name may be in its future.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.